AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25342100
Drug: Intradermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acupuncture (IDA) performed continuously on the subject's skin, stimulated at home every night.
Trial: 23659181
Drug: Dexibuprofen 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen 2.5 or 5 mg/kg (DEX 1)
Trial: 23659181
Drug: Dexibuprofen 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen 3.5 or 7 mg/kg (DEX 2)
Trial: 23659181
Drug: Ibuprofen 5
RxNorm normalized name: ibuprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 5 or 10 mg/kg (control)
Trial: 20033066
Drug: IL-12 plasmid/lipopolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-12 plasmid/lipopolymer complexes (phIL-12/PPC) at doses of 0.6, 3, 12 or 24 mg m(‐2) once every week for 4 weeks
Trial: 12753337
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) administered as 10 MU QD or TIW for 4 weeks, followed by 5 MU QD or TIW for 20 weeks, and then by 3 MU QD or TIW for 24 weeks, in combination with ribavirin (1.0-1.2 g/day)
Trial: 7930412
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of valproate dose
Trial: 3265156
Drug: Corticosteroids (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (intravenous methylprednisolone or oral prednisone) at a standard dose of 80 mg/day for 5 days or variable doses of 20-120 mg/day for 4-20 days, along with trimethoprim-sulfamethoxazole (TMP-SMX)
Trial: 3265156
Drug: Corticosteroids (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (intravenous methylprednisolone or oral prednisone)
Trial: 31061156
Drug: LYS228 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS228 (multiple intravenous doses)
Trial: 31061156
Drug: Placebo (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multiple intravenous doses)
Trial: 31061156
Drug: LYS228 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS228 (single and multiple intravenous doses)
Trial: 25932618
Drug: Memantine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine + Constraint-Induced Aphasia Therapy (CIAT)
Trial: 21691756
Drug: Antidiabetic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic medication (oral antidiabetics, insulin, or both)
Trial: 15265246
Drug: Quetiapine 150-750
RxNorm normalized name: quetiapine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 150-750 mg/day
Trial: 9402380
Drug: Brompheniramine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompheniramine (12 mg) administered at 8:00 A.M. and 8:00 P.M. for ≤ 4 days after onset of symptoms
Trial: 8425662
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin infusion (3056 +/‐ 236 pM)
Trial: 8425662
Drug: Low insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low insulin infusion (486 +/‐ 33 pM)
Trial: 30298673
Drug: Combined antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antioxidant treatment (vitamins, antioxidants, and oligoelements) for six months
Trial: 27323611
Drug: Tongxinluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo Capsule (TC)
Trial: 24777981
Drug: Flaxseed (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (30 g of milled flaxseed/d for 6 months)
Trial: 22456619
Drug: Vitamin D(2),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(2), 2,000 IU daily for 6 weeks (arm A, control)
Trial: 22456619
Drug: Vitamin D(3),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3), 2,000 IU daily for 6 weeks (arm B)
Trial: 22456619
Drug: Vitamin D(2),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(2), 50,000 IU weekly for 6 weeks (arm C)
Trial: 20600512
Drug: 40 mcg
RxNorm normalized name: Caverject 40 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mcg HBV vaccine with 250 mcg GM-CSF
Trial: 20600512
Drug: 40 mcg
RxNorm normalized name: Caverject 40 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mcg HBV vaccine without GM-CSF (control)
Trial: 15987669
Drug: Drug-naïve patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-naïve patients
Trial: 15987669
Drug: Drug-naïve and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-naïve and treated patients
Trial: 9920948
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg) plus methotrexate
Trial: 9208666
Drug: Madopar treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar treatment (26 amblyopia eyes)
Trial: 7356903
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine with 250 mg tetracycline tablets
Trial: 7356903
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 250 mg tetracycline tablets
Trial: 7356903
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine 8 hourly for 6 days with 500 mg tetracycline as tablets
Trial: 7356903
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 500 mg tetracycline as suspension
Trial: 7356903
Drug: Tetracycline tablets
RxNorm normalized name: Oxytetracycline Tablets
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline tablets and suspension
Trial: 26227922
Drug: Peri-articular injections
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-articular injections (PAI)
Trial: 24668608
Drug: 0.05% aspartame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% aspartame solution
Trial: 24668608
Drug: 9.0% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.0% maltodextrin solution
Trial: 22928884
Drug: 30% oral
RxNorm normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% oral glucose
Trial: 15987428
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (1 mg/day of micronized 17beta‐estradiol)
Trial: 15987428
Drug: Combined estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen and progestin therapy (17beta‐estradiol and 5 mg/day of medroxyprogesterone acetate for 12 days/month)
Trial: 2404204
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg per kilogram of body weight per day)
Trial: 31806052
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy (group A)
Trial: 22000747
Drug: Neoadjuvant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiochemotherapy with radiation doses of 50.4 Gy combined with 5-fluorouracil-based chemotherapy
Trial: 12722936
Drug: 8 adjunctive
RxNorm normalized name: ANESTHETIC ADJUNCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 adjunctive hypnosis sessions targeting accelerated wound healing
Trial: 12722936
Drug: 8 adjunctive
RxNorm normalized name: ANESTHETIC ADJUNCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 adjunctive supportive attention sessions
Trial: 10802311
Drug: CS-insulin
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-insulin
Trial: 1643679
Drug: meperidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 0.25 mg.kg‐1
Trial: 1643679
Drug: meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 0.5 mg.kg‐1
Trial: 1643679
Drug: pancuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium 0.06 mg.kg‐1 intravenously
Trial: 6426931
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg valerian (1 capsule Harmonicum Much)
Trial: 6426931
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg valerian (2 capsules Harmonicum Much)
Trial: 26575111
Drug: LNG-IUS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS + low-dose transdermal estradiol (TDE) gel (0.06% containing 0.75 mg of TDE, administered once daily for 50 days)
Trial: 26575111
Drug: LNG-IUS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG-IUS + low-dose transdermal estradiol (TDE) gel
Trial: 12814339
Drug: Calcipotriol +
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol + acitretin combination therapy
Trial: 12814339
Drug: Acitretin monotherapy
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin monotherapy
Trial: 8018618
Drug: Goserelin (GnRH-agonist)
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin (GnRH-agonist)
Trial: 2501801
Drug: Flupenthixol dihydrochloride
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol dihydrochloride (1 to 2 mg/day)
Trial: 2501801
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine maleate (100 to 200 mg/day)
Trial: 576832
Drug: Reproterol (Bronchospasmin)
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol (Bronchospasmin) - i.v. 60 and 90 mug, single peroral administration of 20 mg, long-term therapy with 60 mg in either 3 or 6 daily doses
Trial: 26318552
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical stimulation of the calf muscles for 1 hour session twice daily for the first postoperative week
Trial: 21788224
Drug: Pagibaximab 90
RxNorm normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab 90 mg/kg
Trial: 21788224
Drug: Pagibaximab 60
RxNorm normalized name: Pagibaximab
DrugBank: Pagibaximab (DB17786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagibaximab 60 mg/kg
Trial: 19470769
Drug: Chronomodulated infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronomodulated infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Trial: 19470769
Drug: Conventional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional infusion of 5-fluorouracil, leucovorin, and oxaliplatin
Trial: 15269349
Drug: Beta-adrenergic antagonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic antagonist propranolol administered at encoding
Trial: 11677004
Drug: Moderate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate daily exercise program (n=14)
Trial: 11677004
Drug: No physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No physical activity beyond usual daily requirements (n=11)
Trial: 1867167
Drug: 38% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% phosphoric acid gel for 60 seconds
Trial: 1867167
Drug: 60% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% phosphoric acid gel with 0.5% sodium fluoride for 60 seconds
Trial: 418745
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg diethylcarbamazine daily for five months
Trial: 418745
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg diethylcarbamazine daily for five months
Trial: 418745
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg diethylcarbamazine daily for seven weeks
Trial: 26034151
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg once weekly
Trial: 21594216
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm long implants in augmented bone
Trial: 17210593
Drug: Epoetin alfa,
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa, maximum dosage >100 IU/kg/week during stabilization phase
Trial: 17210593
Drug: Epoetin dosage
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin dosage
Trial: 17210593
Drug: Older age,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older age, higher BMI, anaemia, ACE inhibitor/ARB use, diabetes as primary cause of kidney disease
Trial: 9358616
Drug: Plasma rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma rich in HIV antibodies
Trial: 27352493
Drug: Medication (betahistine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (betahistine mesylate)
Trial: 24561488
Drug: Once-daily voglibose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily voglibose
Trial: 24561488
Drug: Thrice-daily voglibose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily voglibose
Trial: 20647773
Drug: Nimotuzumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (200 mg/dose, once a week for six weeks) with chemoradiation
Trial: 15770976
Drug: G‐SPECT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐SPECT in patients with GEs
Trial: 11926695
Drug: Active ibuprofen
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ibuprofen 5% gel (Ibugel)
Trial: 7543038
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg nalbuphine
Trial: 328192
Drug: Fructose (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (1.2 g.kg‐1)
Trial: 328192
Drug: Dextrose (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose (1.2 g.kg‐1)
Trial: 28589334
Drug: Fixed bearing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed bearing implant
Trial: 28589334
Drug: Mobile bearing
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile bearing implant
Trial: 25741971
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of PCV15
Trial: 21458143
Drug: Free-hand injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free-hand injection without ultrasound guidance
Trial: 19266265
Drug: Polyethyleneoxide (PEO)
RxNorm normalized name: polyethylenimine hydrochloride (20000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethyleneoxide (PEO) based heparin bonded extracorporeal circuits (ECC) + Continuous Leukocyte filtration
Trial: 19266265
Drug: PEO based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEO based heparin bonded ECC without leukofiltration
Trial: 15329029
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (antibacterials only if failed to improve after 7 days)
Trial: 15329029
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment (all patients initially treated with antibacterials)
Trial: 15329029
Drug: Radiology-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiology-guided treatment
Trial: 15329029
Drug: Treatment based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment based on specific clinical criteria
Trial: 10649155
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol plus 30 microg norgestimate
Trial: 10649155
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol plus 90 microg norgestimate
Trial: 10649155
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol plus 180 microg norgestimate
Trial: 10649155
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol daily
Trial: 28660498
Drug: Degarelix 2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 2.8 mg
Trial: 22517190
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (42 mg nicotine patches)
Trial: 21512399
Drug: CR2 (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR2 (0.15 g·kg creatine during 2 d wk of RT)
Trial: 21512399
Drug: CR3 (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR3 (0.10 g·kg creatine during 3 d wk of RT)
Trial: 12964450
Drug: Biofeedback assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback assisted relaxation therapy (BFRT)
Trial: 8712747
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antifungal agent)
Trial: 1681560
Drug: BW234U (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW234U (two different dosage ranges)
Trial: 7036288
Drug: Intraarterial chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial chemotherapy (DTIC 80 mg/m2 + 8 days prior to surgery)
Trial: 7036288
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (vinblastine 6 mg/m2, thiotepa 6 mg/m2, rufocromycine 60 microgram/m2, methotrexate 15 mg/m2 on day 1, procarbazine 30 mg/m2 for 7 days)
Trial: 7036288
Drug: Chemoimmunotherapy (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (chemotherapy identical to above + DTIC 300 mg/m2 for each course + BCG every 4 weeks + C. parvum every week)
Trial: 31808709
Drug: Open-label chamomile
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label chamomile extract 1500 mg daily for 8 weeks
Trial: 31801593
Drug: Fire needle
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needle therapy (group A1)
Trial: 31801593
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment (group B)
Trial: 26564598
Drug: Evacetrapib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib monotherapy
Trial: 26564598
Drug: Statin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin monotherapy (rosuvastatin and simvastatin)
Trial: 26564598
Drug: Evacetrapib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib monotherapy and evacetrapib combined with statins
Trial: 16317063
Drug: Regular +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular + NPH insulin (R+N)
Trial: 15623591
Drug: Thalidomide 400
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 400 mg daily
Trial: 15623591
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg on alternate days
Trial: 12194618
Drug: Independent practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent practice of sitting balance as an addition to standard physiotherapy treatment based on the Bobath Approach for four weeks.
Trial: 12194618
Drug: Standard physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physiotherapy treatment based on the Bobath Approach (control group).
Trial: 2088195
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg) + Clindamycin (600 mg)
Trial: 2088195
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) + Clindamycin (600 mg)
Trial: 2088195
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg) + Clindamycin (600 mg)
Trial: 2088195
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg) + Metronidazole (500 mg)
Trial: 2088195
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg) + Metronidazole (400 mg)
Trial: 2088195
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg) + Metronidazole (400 mg)
Trial: 2088195
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg) + Ornidazole (500 mg)
Trial: 520100
Drug: Aspirin (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3600 mg/d)
Trial: 520100
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg/d)
Trial: 520100
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg/d)